Can the probability of radiation esophagitis be reduced without compromising lung tumor control: A radiobiological modeling study

References

• Vansteenkiste J, De Ruysscher D, Eberhardt WEE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi89–98.
   PubMedGoogle Scholar
• Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p. Lancet Oncol 2015;16:187–99.
   PubMed Web of Science ®Google Scholar
• Wiersma TG, Dahele M, Verbakel WFaR, van de Ven PM, de Haan PF, Smit EF, et al. Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer. Lung Cancer 2013;80:62–7.
   PubMed Web of Science ®Google Scholar
• Bradley J, Paulus R, Komaki R. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small. J Clin Oncol 2013;17–18.
   PubMed Web of Science ®Google Scholar
• O’rourke N, Roqué I Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;CD002140
   Google Scholar
• Kwint M, Uyterlinde W, Nijkamp J, Chen C, de Bois J, Sonke J-J, et al. Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. Int J Radiat Oncol Biol Phys 2012;84:e223–8.
   PubMed Web of Science ®Google Scholar
• Palma Da, Senan S, Oberije C, Belderbos J, Dios NR, De, et al. Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-analysis. Int J Radiat Oncol Biol Phys 2013;87:690–6.
   PubMed Web of Science ®Google Scholar
• Uyterlinde W, Chen C, Kwint M, de Bois J, Vincent A, Sonke J-J, et al. Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. Radiother Oncol 2013;107:392–7.
   PubMed Web of Science ®Google Scholar
• Huang EX, Bradley JD, El Naqa I, Hope AJ, Lindsay PE, Bosch WR, et al. Modeling the risk of radiation-induced acute esophagitis for combined Washington University and RTOG trial 93-11 lung cancer patients. Int J Radiat Oncol Biol Phys 2012;82:1674–9.
   PubMed Web of Science ®Google Scholar
• Singh A, Lockett M, Bradley J. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol 2003;55:337–41.
   PubMed Web of Science ®Google Scholar
• Chapet O, Kong F-M, Lee JS, Hayman JA, Ten Haken RK. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 2005;77:176–81.
   PubMed Web of Science ®Google Scholar
• Lyman J. Complication probability as assessed from dose-volume histograms. Radiat Res 1985;19:13–19.
   Google Scholar
• Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997;24:103–10
   Google Scholar
• Chapet O, Thomas E, Kessler ML, Fraass BA, Ten Haken RK. Esophagus sparing with IMRT in lung tumor irradiation: an EUD-based optimization technique. Int J Radiat Oncol Biol Phys 2005;63:179–87.
   PubMed Web of Science ®Google Scholar
• Niedzielski JS, Bluett JB, Williamson RT, Liao Z, Gomez DR, Court LE. Analysis of esophageal-sparing treatment plans for patients with high-grade esophagitis. J Appl Clin Med Phys 2013;14:163–70.
   Web of Science ®Google Scholar
• Dieleman EMT, Senan S, Vincent A, Lagerwaard FJ, Slotman BJ, van Sörnsen de Koste JR. Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. Int J Radiat Oncol Biol Phys 2007;67:775–80.
   PubMed Web of Science ®Google Scholar
• Blom GJ, Verbakel Wfar Dahele M, Hoffmans D, Slotman BJ Senan S. Improving radiotherapy planning for large volume lung cancer: A dosimetric comparison between hybrid-IMRT and RapidArc. Acta Oncol (Madr) 2015;54:427–32.
   PubMed Web of Science ®Google Scholar
• Verbakel Wfar van Reij E, Ladenius-Lischer I, Cuijpers JP, Slotman BJ Senan S. Clinical application of a novel hybrid intensity-modulated radiotherapy technique for stage III lung cancer and dosimetric comparison with four other techniques. Int J Radiat Oncol Biol Phys 2012;83:e297–303.
   PubMed Web of Science ®Google Scholar
• Källman P, Ågren A, Brahme A. Tumour and normal tissue responses to fractionated non-uniform dose delivery. Int J Radiat Biol 1992;62:249–62.
   PubMed Web of Science ®Google Scholar
• Werner-Wasik M, Yorke E, Deasy J, Nam J, Marks LB. Radiation dose-volume effects in the esophagus. Int J Radiat Oncol 2010;76:S86–93.
   PubMed Web of Science ®Google Scholar
• Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon J, Van, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009;91:386–92.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Richter A, Wilbert J, Flentje M, Partridge M. Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. Int J Radiat Oncol Biol Phys 2011;81:e275–82.
   PubMed Web of Science ®Google Scholar